Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer reports positive data from RA drug trial

Pfizer reports positive data from RA drug trial

9th November 2010

Pfizer has published new clinical data which supports the efficacy of its developmental therapy for moderate-to-severe rheumatoid arthritis (RA).

Results from the first phase III trial of tasocitinib, an oral JAK inhibitor, showed that it can deliver significant improvements in signs and symptoms of the disease compared to placebo, as well as helping patients to maintain physical function.

It means the drug met two of its primary endpoints in the study, while it was also shown to be associated with a greater number of cases of disease remission.

This comes after data from an earlier phase II/III trial showed that tasocitinib can deliver sustained effectiveness over 24 months, whether administered as a monotherapy or in combination with methotrexate.

Dr Roy Fleischmann, clinical professor at the University of Texas Southwestern Medical Center, said: "We are encouraged by the statistically significant and clinically meaningful improvements we observed in a proportion of patients treated with tasocitinib."

Earlier this month, the company posted its financial results for the third quarter of 2010, reporting significant year-on-year growth following its late 2009 merger with Wyeth.ADNFCR-8000103-ID-800224524-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.